PRECIGEN Investors

Events

Precigen Business and Clinical Update

Apr 04, 2023 at 8:30 AM EDT

Precigen will host a conference call to provide business and clinical updates for recent announcements.

Supporting Materials

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®

Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors